Paid clinical trial for healthy volunteers aged 21 to 40.

Receive a payment for your time!

Study summary

We are carrying out a clinical trial with an investigational drug that is being developed with the intention of treating idiopathic pulmonary fibrosis (IPF). IPF is a chronic and fatal lung disease with an unknown cause (idiopathic). Many existing IPF drugs are ineffective and are not well tolerated.

Paid clinical trial for healthy volunteers
Register your interest in this clinical trial

The main purpose of the study will be to investigate how long the drug will remain in the body, but we will also study its overall safety and tolerability. The information gathered during this clinical trial may be used to support further drug development, including larger trials in patients with IPF.

This study will be conducted at our clinical trials unit in London Bridge located on Newcomen Street and will involve healthy male and female volunteers.

The trial will take approximately 7 weeks to complete and it is made up of the following parts:

  • Screening visit: Will be within or up to 20 days before admission where you are assessed to determine if you can be included into the trial.
  • Treatment Period: The treatment period lasts for 19 days /18 nights and you will need to stay in our clinical trials unit for this time.
  • Outpatient visit: You will be required to attend out-patient visits on Day 20 and Day 24.
  • Final follow-up visit: You will be required to attend a final follow-up on Day 28.


Study dates

Part B (MAD)

Cohort 2

  • Screening period: July 09th – July 23rd (only 1x screening appointment required)
  • In-house period: July 26th – August 13th
  • Outpatient visits:  Wednesday 15th August & Sunday 19th August
  • Follow-up visit: Thursday 23rd August


Who can take part?

To be eligible to take part in this study you must fit the following criteria:

  • Healthy male or female volunteers aged between 21 and 40 (inclusive).
  • You must have a body weight of between 55 and 105 kg, inclusive, and A Body Mass Index (BMI) between 18.0-30.0 kg/m² inclusive.
  • You must not have used tobacco in any form, used smoking cessation or other nicotine-containing products three months prior to dosing.
  • You must not test positive hepatitis B/C, HIV, alcohol or drugs or show any evidence of drug or alcohol abuse.
  • You must not have not donated more than 1.5 litres of blood (males)/ 1.0 litres of blood (females) within 10 months prior to the first dosing.
  • You must be healthy with no underlying medical conditions that may either interfere with participation in the clinical study, and/or put you at any significant risk.
  • Female volunteers must be of non-childbearing potential e.g. post-menopausal or permanently sterile.
  • Male volunteers must be willing to use appropriate contraception throughout the study and for at least three months after the last follow-up visit.

A full list of acceptable contraceptive methods will be discussed in full by a member of the recruitment team and a study doctor during screening.

Study payment
In recognition of the time and effort involved in taking part in this study, you will receive up to £2,778 (£1000 bonus and £1778 study payment) on completion of the study provided you comply fully with all the study requirements.

Get in touch
Call our team for more information: +44 (0) 20 7042 5800 (opt 1)
We are open weekdays 9am-5pm
or email us: volunteer@richmondpharmacology.com

Register your interest in this clinical trial

Ref: C17056_Feb2018 (email_website_advert text)

The contents of this page have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.

You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit.